gepirone Exxua
Selected indexed studies
- Gepirone (Exxua) for depression. (Med Lett Drugs Ther, 2024) [PMID:38905523]
- The Black Book of Psychotropic Dosing and Monitoring. (Psychopharmacol Bull, 2024) [PMID:38993656]
- Gepirone Extended-Release: First Approval. (Drugs, 2023) [PMID:38079093]
_Worker-drafted node — pending editorial review._
Connections
gepirone Exxua is a side effect of
Sources
- The Black Book of Psychotropic Dosing and Monitoring. (2024) pubmed
- Gepirone. (2006) pubmed
- Gepirone Extended-Release: First Approval. (2023) pubmed
- Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties. (2019) pubmed
- Gepirone: A New Extended-Release Oral Selective Serotonin Receptor Agonist for Major Depressive Disorder. (2024) pubmed
- Gepirone. Organon. (2001) pubmed
- Gepirone (Exxua) for depression. (2024) pubmed
- A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone. (2003) pubmed
- Gepirone (Exxua) for the Treatment of Major Depressive Disorder. (2025) pubmed
- Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications. (2025) pubmed